test2017-11-03T13:28:42-05:00

Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML

Cullinan Oncology, German Cancer Research Center (DKFZ) and the [...]

September 15, 2020|

Cullinan Oncology Secures $150 Million Series A Financing To Build Innovative Development Company

CAMBRIDGE, Mass., October 3, 2017 - - Cullinan Oncology, LLC announced today a $150 million Series A financing co-led by the UBS Oncology Impact Fund (OIF) managed by MPM Capital, a worldwide leader in oncology investing, and F2 Ventures.

October 3, 2017|Tags: |
Go to Top